PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra ...

PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to partic ...

Integra LifeSciences Holdings Corporation (IART) is well-poised to grow in the coming quarter, driven by healthy sales growth within its Tissue Technologies business despite product recall and manufacturing pause in Boston. The strong performance of the company's Codman Specialty Surgical (CSS) arm is encouraging. Meanwhile, headwinds such as a dull macro environment and currency fluctuations pose concerns for Integra's operations. In the past year, this Zacks Rank #3 (Hold) stock has lost 55.1% against the ...

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciences At Integra Li ...

ESG Report Highlights - Integra LifeSciences issued its latest ESG report, highlighting the company's 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago [1] - The company's president and CEO emphasized the importance of innovating treatment pathways to advance patient outcomes and set new standards of care [2] - Integra's ESG report includes highlights in key areas: Environmental, Social, and Governance [2] Environmental Initiatives - Recalculated Scope 1, 2, and 3 emissions and partnered with an external consultant to conduct energy assessments at highest energy usage locations to identify energy reduction opportunities and improve greenhouse gas footprint [2] Social Initiatives - Bolstered diversity and inclusion efforts by adding a new employee resource group [2] - Focused on early-in-career talent by providing support and hands-on experience to diverse college students and graduates [2] Governance Initiatives - Revised Code of Conduct and continued to strengthen anti-bribery and corruption program through ongoing training curriculums and programs [2] Alignment with External Guidelines - Integra prepared its ESG report in alignment with external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index [2] Company Overview - Integra LifeSciences is driven by its purpose of restoring patients' lives and innovates treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care [4] - The company offers a comprehensive portfolio of high quality, leadership brands [4]

Revenue Discussion Tissue Technologies revenues totaled $116.4 million in the second quarter, up 5.6% year over year on a reported basis and 5.7% on an organic basis. The upside was due to the impact of high-double-digit growth in DuraSorb, mid-double-digit growth in Gentrix, along with low double-digit growth in MicroMatrix, Cytal and amniotics. Overall, adjusted operating profit were $0.7 million, down 95.6% year over year. Adjusted operating margin saw a 391-bps contraction year over year to 0.2%. Guidan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Registrant's Telephone Number, Including Area Code: (609) 275-0500 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark wh ...

The company posted a loss per share of $0.16, based on generally accepted accounting principles (GAAP). Integra announced adjusted earnings per share (EPS) of $0.63. Although this reflected a decline from adjusted EPS of $0.71 in the prior-year period, it narrowly beat the consensus estimate of $0.62. Shares of Integra Lifesciences (IART -17.88%) were sinking 15.5% as of 11 a.m. ET on Monday. The decline came after the medical technology company announced its second-quarter results before the market opened. ...

Financial Data and Key Metrics Changes - The company reported Q2 revenues of approximately $418 million, representing a 9.7% growth on a reported basis and 2.3% on an organic basis compared to the prior year [11][16] - Adjusted EPS for the quarter was $0.63, down 11% compared to 2023 [16] - Adjusted EBITDA margins were 20%, down 330 basis points compared to 2023, primarily due to a decrease in gross margins [34][62] - Operating cash flow for the second quarter was $40 million [34] Business Line Data and Key Metrics Changes - The Codman Specialty Surgical (CSS) business reported Q2 revenues of $302 million, up 11.3% on a reported basis and 0.9% on an organic basis [17] - The ENT business saw 18% growth for the second quarter, reflecting early synergies from the Acclarent acquisition [35] - Tissue Technologies increased 5.6% on a reported basis and 5.7% on an organic basis, with high-double-digit growth in DuraSorb [36] Market Data and Key Metrics Changes - Global sales in neurosurgery grew 1.2% on an organic basis, with strong growth in certain franchises offset by backorders [17] - International business saw low-single-digit growth, with strong demand in many markets but unable to meet demand due to backorders [18] Company Strategy and Development Direction - The company is focused on a compliance master plan to improve quality systems and GMP compliance across its manufacturing and supply network, which will increase spending in the second half of 2024 [6][7] - The company remains committed to bringing PriMatrix and SurgiMend back to market and believes in its product portfolio and long-term growth prospects despite recent performance [8][12] - The integration of Acclarent is expected to expand addressable markets and provide immediate scale and accretive growth [29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged operational and quality system gaps and emphasized the need for investments to strengthen compliance processes [23][24] - The company expects revenue and adjusted EPS guidance for the year to be impacted by supply holds and backorders, with a forecasted revenue range of $1.609 billion to $1.629 billion [31][70] - For 2025, the company anticipates mid-single-digit organic revenue growth, but also pockets of supply disruption due to the compliance master plan [43] Other Important Information - The company has total liquidity of $1.2 billion, including $297 million in cash and short-term investments [39] - The Braintree facility is expected to be operational in the first half of 2026, which will support the production of SurgiMend and PriMatrix [59][135] Q&A Session Summary Question: Can you provide more color on the shipping holds in Q3? - Management stated that the temporary shipping holds impact several SKUs across the CSS business and expects most holds to be cleared by Q3 [46][47] Question: Why are you confident that the shipping holds won't extend into 2025? - Management expressed confidence based on their plan to clear the majority of holds by the end of 2024, indicating that the issues are isolated to 2024 [50][51] Question: What are the anticipated investments over the next 18 months? - Investments will focus on improving quality compliance and supply chain capabilities, with capital spending expected to remain consistent with 2024 levels [101] Question: How do you plan to retain your sales force amid these challenges? - Management emphasized the importance of supporting the sales force to maintain relationships with customers and drive future growth [95][112] Question: What is the expected contribution of Acclarent to growth in 2025? - Acclarent is expected to contribute positively to growth, with the company seeing continued strength across other parts of the business [138]

Over the last four quarters, the company has surpassed consensus EPS estimates just once. Integra shares have lost about 27.8% since the beginning of the year versus the S&P 500's gain of 14.5%. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Investors should be mindf ...